Downloads
Abstract
Introduction: Epithelial ovarian cancer is a malignant abnormality of the epithelial cell of the ovary.
The disease has a poor prognosis. Despite optimal initial therapy, the majority of patients will relapse
and require further treatment. Treatment of recurrent ovarian cancer is still challenging. This study aims
to describe clinical and subclinical characteristics of patients with platinum - resistant relapsed ovarian
carcinoma and evaluate the treatment results of the paclitaxel regimen on these patients. Methods: We enrolled 65 patients with platinum - resistant recurrent epithelial ovarian cancer treated
with paclitaxel regimen, met the inclusion and exclusion criteria.
Results: The most common recurrent sites were lymph nodes (54.3%), peritoneum (50%), and liver
(23.9%). CA125 increased at the time of recurrence (77.8%), the overall response rate was 22.5%.
Disease control rates (including complete response, partial response, and stable disease) were achieved
at 62.5%. Median progression - free survival was 26.1 weeks (95% CI: 20.9 - 28.4). Hematopoietic system
toxicities include neutropenia of grade 1, 2. Hepatotoxicity occupied 9.3%, mainly liver enzymes elevation
of grade 1, 2. No renal toxicity was observed. Other undesirable effects include hair loss of grade 2 (2.7%),
stomatitis(2.1%), sensory nerve 15% but only grade 1. There was a relationship between treatment
response and CA 125 levels.
Conclusion: The paclitaxel regimen used to treat platinum - resistant recurrent epithelial ovarian cancer
is the appropriate regimen in terms of efficacy and safety. After several lines of chemotherapy regimens.
References
Bùi Diệu. Sổ tay điều trị nội khoa ung thư. Nhà
xuất bản Y học, Trường Đạihọc Y Hà Nội.
;168-173.
Trần Văn Thuấn, Bùi Diệu. Chẩn đoán và điều trị
bệnh ung thư. Nhà xuất bản Y học, Trường Đại
học Y Hà Nội; 2007;339-351.
Heintz A, Odicino F, Maisonneuve P et al.
Carcinoma of the fallopian tube. Journal of
epidemiology and biostatistics. 2001;1(6):89-103.
Ezcurdia L, Jovtis SL, Mickiewicz E et al.
Paclitaxel in platinum - resistant ovarian cancer
patients. Argentine multicenter taxol group.
Seminars in oncology.1997;5(24):15-53.
Markman M, Blessing J, Rubin SC et al. Phase
ii trial of weekly paclitaxel (80 mg/m2 ) in platinum and paclitaxel - resistant ovarian and
primary peritoneal cancers: a gynecologic
oncology group study. Gynecologic oncology.
;3(101):436-440.
Amate P, Huchon C, Dessapt AL et al. Ovarian
cancer: sites of recurrence. International Journal
of Gynecologic Cancer. 2013; 9.
Seewaldt VL, Greer BE, Cain JM et al. Paclitaxel
(taxol) treatment for refractory ovarian cancer:
phase II clinical trial. American journal of obstetrics
and gynecology 1994; 5(170): 1666-1671.
Gore M, Levy V, Rustin G et al. Paclitaxel (taxol)
in relapsed and refractory ovarian cancer: the uk
and eire experience. British journal of cancer.
;4(72):1016-1019.
| Published | 30-11-2021 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 74 (2021) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.2021.74.8 | |
| Keywords | Ung thư buồng trứng tái phát, kháng platinum, paclitaxel. Recurrent epithelial ovarian cancer, platinum - resistant, paclitaxel. |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2021 Journal of Clinical Medicine Hue Central Hospital